Georgia Gourgioti

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

Dimitrios Pectasides, Vasilios Karavasilis, George Papaxoinis et al. · BMC Cancer · 2015 · 51 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study

Axel S. Merseburger, Gerhardt Attard, Lennart Åström et al. · The Lancet Oncology · 2022 · 39 citations

Medicine, Oncology, Pharmacology +14

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin

Stacey A. Cohen, Chen Wu, Ming Yu et al. · Clinical Colorectal Cancer · 2015 · 28 citations

Medicine, Molecular Genetics, Oncology +16

Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial

George Pentheroudakis, Georgia Raptou, Vassiliki Kotoula et al. · PLoS ONE · 2015 · 24 citations · Full text

Medicine, Immunology, Oncology +17

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

Maria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando et al. · European Urology Oncology · 2024 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17